With GLP-1 therapies expected to be a significant revenue driver in the future, Biocon aims to strengthen its footprint in this segment.

Despite the sharp decline, the regulatory setback isn't as severe as it seems—the letter only raises compliance concerns without halting operations or triggering an import alert.

Regulatory changes, such as the US Biosecure Act, may accelerate growth for CDMO businesses. However, uncertainties remain, especially if Donald Trump returns to power. Trump has criticized India on trade issues, including pharmaceutical tariffs, which could impact domestic pharma strategies.

The Company Receives Establishment Inspection Report (EIR) from the U.S. FDA for Its Manufacturing Facility in Somerset, New Jersey

Company's Board Approves Marketing and Supply Agreement with Mylan Pharmaceuticals

The stock gave multibagger returns of over 200 per cent from its 52-week low of Rs 58.20 per share.

The company’s shares have delivered a multibagger return of over 200 per cent in the past 1 year.

The stock gave multibagger returns of 1,460 per cent in 2 years, 2,300 per cent in 3 years and a whopping 14,200 per cent in 5 years.

Transgene Biotek Ltd.'s partnership with NiedlFree Technologies has the potential to revolutionize the way people with diabetes manage their condition. Oral insulin delivery could eliminate the need for painful injections and make it easier for people to adhere to their treatment plans. This could lead to improved health outcomes and a better quality of life for millions of people worldwide.

Given the shared traits between the pharmaceutical and IT industries,

The corona virus pandemic drew everyone's attention to the need for basic medical facilities across the country, elevating the pharmaceutical and healthcare industries and compelling the government to pay greater attention to them. Mandar Wagh describes how being a major participant in terms of both volume and value globally, the government's emphasis and initiatives all contribute to the success of the industry

The company offers a diverse portfolio of products and services, including APIs, generics, branded generics, biosimilars and over-the-counter medications. With a history of scientific advancements and industry-first achievements, the company remains committed to investing in future business opportunities.

After a prolonged correction, the index underwent another surge in recent times as healthcare stocks gained momentum due to the deteriorating Covid scenario. 

The company released a press release on Monday, stating Advent International has entered into definitive agreement to acquire significant stake in the company and intends to explore the merger of  its portfolio company

At the time of market closing on Monday, the headline equity indices, i.e. Sensex and Nifty 50 plunged over a per cent each, owing to the rising inflation fears in the US markets.  

At 11.30 am on Friday, the headline equity indices, i.e. Sensex and Nifty 50 are seen extending their losing streak in the morning, owing to weak global cues.  

The pharmaceutical sector in India ranks third in terms of volume and fourteenth in terms of value (both globally).  The domestic market is anticipated to increase three times in the next ten years, according to the Indian Economic Survey 2021.

In Q4FY22, the financial performance of the pharma companies was affected by the rising raw material & freight costs. Despite the pressure on margins, some pharmaceutical companies managed to showcase decent financial performance in Q4FY22. 

In the first hour of the trading session, Sensex and Nifty were able to recover some of the opening losses and traded flat. At the time of market opening, 27 out of 30 stocks on Sensex were trading in the red. The top gainers on Sensex are Dr Reddy’s Laboratories, Reliance Industries, and Maruti Suzuki whereas the top losers include Asian Paints, Tata Steel, Power Grid Corporation, L&T, and UltraTech Cement.  

The stock of Aurobindo Pharma is extremely bullish today and has surged nearly 2 per cent despite turmoil in the market.

Shilpa Biologicals Pvt Ltd, a subsidiary of Shilpa Medicare Ltd, has announced a strategic tie-up with Mylab Discovery Solutions, India’s leading diagnostic solutions provider. With this association, Shilpa Medicare expects to venture into the vaccine and therapeutics segment